Pancragen: A Beneficial Aid for Pancreatic Health

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.

Overview

With the accelerating aging of the population in modern society, diseases related to pancreatic function, such as type 2 diabetes and impaired glucose tolerance, have become increasingly prominent. Pancragen, a tetrapeptide, has garnered significant attention in recent years in the field of pancreatic health research.

Figure 1 The chemical structure of Pancragen.

The Regulatory Effects of Pancragen on Pancreatic Endocrine Function

Glucose Regulation

In studies on elderly rhesus monkeys, it was found that after administration of a standard dose of glucose, the “disappearance” rate of glucose was lower in elderly animals compared to young animals, indicating reduced glucose clearance capacity. However, when elderly rhesus monkeys were administered Pancragen via intramuscular injection (50 μg/animal/day for 10 days), the “disappearance” rate of glucose was significantly increased. This indicates that Pancragen can enhance the body's metabolic capacity for glucose, promoting faster clearance of blood glucose and maintaining stable blood glucose levels. This mechanism of action is related to Pancragen's regulation of pancreatic endocrine cells, as it can stimulate insulin secretion or enhance insulin sensitivity, thereby increasing peripheral tissue uptake and utilization of glucose and lowering blood glucose levels.

Regulation of insulin and C-peptide levels

The study also showed that after glucose administration, the peak levels of insulin and C-peptide (5 and 15 minutes after glucose injection) were higher in elderly animals than in younger animals. This indicates that insulin secretion patterns in aged animals are abnormal. The use of Pancragen restores normal plasma insulin and C-peptide kinetics. C-peptide is secreted in equal molar amounts with insulin, and changes in its levels reflect the function of pancreatic β-cells. Pancragen restores normal insulin and C-peptide levels, indicating its positive regulatory effect on pancreatic β-cell function, which helps maintain normal insulin secretion rhythms. This is crucial for stabilizing blood glucose levels and ensuring normal glucose metabolism in the body.

Pancragen and Improvement of Impaired Glucose Tolerance

Animal Experiment Results

Nine clinically healthy elderly female rhesus monkeys aged 20–25 years were used as study subjects. of which 5 were injected with Pancragen (0.05 mg/animal/day, intramuscular injection, for 10 days), and 4 were administered the commonly used antidiabetic drug glimepiride (4 mg/animal/day, oral administration, for 10 days). Both Pancragen and glimepiride reduced the basal blood glucose levels of elderly monkeys. Pancragen not only lowers blood glucose, but also restores insulin and C-peptide levels to normal, demonstrating a restorative effect on impaired glucose tolerance in aged animals. Pancragen exhibits unique advantages in improving impaired glucose tolerance, as it not only reduces blood glucose levels but more importantly addresses the root cause by regulating pancreatic endocrine function, thereby enhancing the body's ability to tolerate glucose.

Potential clinical implications

Impaired glucose tolerance is the prediabetic stage of type 2 diabetes, and if left unaddressed, it can easily progress to diabetes. Pancragen's ability to improve glucose tolerance in aged animals offers new insights for the prevention and treatment of type 2 diabetes. For individuals in the impaired glucose tolerance stage, particularly the elderly, Pancragen may serve as a safe and effective intervention to delay or prevent the progression to diabetes.

The Promoting Effect of Pancragen on Pancreatic Cell Differentiation

Regulation of the Expression of Cell Differentiation Markers

Research has shown that as pancreatic cells age, the expression of differentiation markers decreases. However, Pancragen can stimulate the expression of pancreatic differentiation factors (such as PDX1 and PTFLA) and islet cell markers (PDX1, PAX6, PAX4, FOXA2, and NKX2.2) in both “young” and “aged” cultures. These differentiation factors are crucial for the normal differentiation and functional maintenance of pancreatic cells. PDX1 is a key regulator of pancreatic development and pancreatic β-cell function, and its increased expression helps promote the differentiation and functional recovery of pancreatic β-cells. Pancragen promotes the differentiation of pancreatic cells into normal functional cells by upregulating the expression of these differentiation markers.

Differentiation Mechanism and Health Implications

Pancragen induces the differentiation of pancreatic islet and acinar cells, a process that is one of the key mechanisms underlying its anti-diabetic and anti-inflammatory effects. By promoting cell differentiation, Pancragen helps maintain the structural and functional integrity of pancreatic tissue, enhances the pancreas's ability to regulate blood glucose levels, and reduces inflammatory damage to pancreatic tissue. This promotion of pancreatic cell differentiation provides a potential therapeutic target for treating pancreatic-related diseases such as diabetes and pancreatitis.

Application Potential of Pancragen in the Elderly Population

Addressing Age-Related Pancreatic Dysfunction

In the modern societal demographic structure, the significant increase in the elderly population is one of the primary reasons for the rising number of patients with type 2 diabetes and impaired glucose tolerance. The positive effects of Pancragen on pancreatic endocrine function in elderly non-human primates suggest its broad application potential in the elderly population. It can effectively regulate and improve age-related pancreatic dysfunction in the elderly, helping them maintain normal blood glucose levels and pancreatic function.

Conclusion

In summary, Pancragen has demonstrated multifaceted positive effects in the field of pancreatic health. It can regulate pancreatic endocrine function, effectively improve blood glucose levels and the secretion patterns of insulin and C-peptide; it has a good restorative effect on impaired glucose tolerance, providing new strategies for the prevention and treatment of type 2 diabetes; by promoting pancreatic cell differentiation, it maintains the stability of pancreatic tissue structure and function, playing an important role in the treatment of diseases such as diabetes and pancreatitis.

Sources

[1] Goncharova N D, Ivanova L G, Oganyan T E, et al. [Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys][J]. Advances in Gerontology, 2015,28(3):579-585.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=28509500&query_hl=1

[2] Goncharova N D, Ivanova L G, Oganian T É, et al. [Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys][J]. Advances in Gerontology, 2014,27(4):662-667.http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=25946840&query_hl=1

[3] Khavinson V, Durnova A O, Polyakova V O, et al. Effects of pancragen on the differentiation of pancreatic cells during their ageing[J]. Bulletin of Experimental Biology and Medicine, 2013,154(4):501-504.DOI:10.1007/s10517-013-1987-6.

Product available for research use only: